Development of CIRC Technologies
Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particular
| Condition(s) | Cardiovascular Diseases, Heart Failure, Ischemic Heart Disease, Non-ischemic Cardiomyopathy, Valvular Heart Disease, Metabolic Cardiomyopathy, Congenital Heart Disease, Aortic Diseases, Atrial Fibrill |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow us the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases. Our team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotyp |
| Who can participate | Inclusion Criteria: * Age ≥ 18 years of age * Provision of written informed consent * If not healthy volunteer, must be diagnosed with cardiovascular disease Exclusion Criteria: * Vulnerable populations will be excluded from this study including Prisoners * Other contraindications to CMR imaging to be determined by standard MRI protocols * Decisionally impaired (e.g., dementia or cognitive disability) |
| Ages | 18 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | The Cleveland Clinic |
| Locations | Cleveland, Ohio, United States |
| Start date | 2022-09-09 |
| NCT ID | NCT05654272 |
| Official listing | https://clinicaltrials.gov/study/NCT05654272 |